Jing Liao

Company: Alexion Pharmaceuticals

Job title: Director - Vector Operations

Seminars:

Next-Gen Plasmid Design mAAVRx Achieves High-Yield, High-Quality And Potent AAV Vectors In Scalable Suspension Hek293 Cells 3:00 pm

• Novel plasmid design mAAVRx enhances the AAV manufacturability by increasing crude harvest titer dramatically • mAAVRx increases the vector purity with higher non-empty capsid%, lower residual plasmid DNA and non-detectable rcAAV contaminants • mAAVRx maintains the potency of the vector both in vitro and in vivoRead more

day: Day Two PM